Italy· 034529040
SYNAGIS*1 flaconcino IM 1 ml 100 mg/ml
A palivizumab product containing palivizumab, registered in Italy by ASTRAZENECA AB, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Italy
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
- Active substance
- Palivizumab
- Manufacturer
- ASTRAZENECA AB
- Country
- Italy (IT)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic034529040SYNAGIS*1 flaconcino IM 1 ml 100 mg/mlEUR 1493.33
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSynagis2care4 ApS
- SpainSYNAGIS 100 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEAstrazeneca Ab
- United KingdomSynagis 100mg powder and solvent for solution for injection vialsAbbVie Ltd
- BelgiumSynagis 100 mgAstraZeneca
- NorwaySynagisAstraZeneca
- United StatesSynagisSwedish Orphan Biovitrum AB (publ)
- CanadaSYNAGISASTRAZENECA CANADA INC
- SwitzerlandSynagis 100 mg/1 ml, InjektionslösungAstraZeneca AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/744b0758-01c8-4a08-bdaf-55896b5a20ac GET /v1/drugs/744b0758-01c8-4a08-bdaf-55896b5a20ac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 1493.33,
"source": "aifa",
"currency": "EUR",
"strength": "PALIVIZUMAB 100MG 1 UNITA' USO PARENTERALE",
"substance": "Palivizumab",
"equivalence_group": "BHG",
"transparency_flag": null
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.